Does the media refer more to SUPN or PRGO?

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 4 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.89 beat Perrigo's score of 0.57 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRGO or NKTR?

In the previous week, Perrigo had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.82 beat Perrigo's score of 0.57 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PRGO or PCRX?

In the previous week, Perrigo had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.94 beat Perrigo's score of 0.57 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRGO or OMER more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -43.50% 9.96% 3.90% Omeros N/A -102.16% 64.87%

Does the media favor PRGO or OMER?

In the previous week, Omeros had 3 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Perrigo. Perrigo's average media sentiment score of 0.57 beat Omeros' score of 0.57 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRGO or ASMB?

In the previous week, Perrigo had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.94 beat Perrigo's score of 0.57 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Perrigo (PRGO) Competitors

$10.16 -0.06 (-0.54%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$10.38 +0.21 (+2.08%)

As of 04:31 AM Eastern

Compare

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

Should you buy Perrigo stock or one of its competitors? MarketBeat compares Perrigo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Perrigo include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Supernus Pharmaceuticals presently has a consensus target price of $62.83, suggesting a potential upside of 32.70%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 90.20%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Supernus Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Supernus Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.82	-$38.55M	-$0.51	N/A
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Perrigo	-43.50%	9.96%	3.90%

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 4 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.89 beat Perrigo's score of 0.57 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.9% of Perrigo shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Perrigo on 11 of the 15 factors compared between the two stocks.

How does Perrigo compare to Nektar Therapeutics?

Perrigo (NYSE:PRGO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nektar Therapeutics has lower revenue, but higher earnings than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Nektar Therapeutics	$55.23M	41.80	-$164.08M	-$8.42	N/A

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 90.20%. Nektar Therapeutics has a consensus price target of $149.63, suggesting a potential upside of 119.01%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Perrigo had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.82 beat Perrigo's score of 0.57 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Perrigo compare to Pacira BioSciences?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Perrigo had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.94 beat Perrigo's score of 0.57 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.38	$7.03M	$0.12	212.83

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 90.20%. Pacira BioSciences has a consensus price target of $29.40, suggesting a potential upside of 15.11%. Given Perrigo's higher possible upside, equities analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Pacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Omeros?

Perrigo (NYSE:PRGO) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Omeros has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.30

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Perrigo currently has a consensus price target of $19.33, indicating a potential upside of 90.20%. Omeros has a consensus price target of $38.00, indicating a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Omeros had 3 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Perrigo. Perrigo's average media sentiment score of 0.57 beat Omeros' score of 0.57 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Omeros has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Omeros	N/A	-102.16%	64.87%

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Assembly Biosciences?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Assembly Biosciences	$72.30M	5.93	-$6.12M	-$0.11	N/A

Perrigo presently has a consensus target price of $19.33, suggesting a potential upside of 90.20%. Assembly Biosciences has a consensus target price of $44.00, suggesting a potential upside of 63.20%. Given Perrigo's higher probable upside, equities research analysts plainly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Perrigo had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.94 beat Perrigo's score of 0.57 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Summary

Assembly Biosciences beats Perrigo on 9 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.41B	$8.82B	$7.05B	$23.46B
Dividend Yield	11.35%	2.54%	2.68%	4.02%
P/E Ratio	-0.78	16.09	27.13	31.08
Price / Sales	0.33	7.04	589.11	19.77
Price / Cash	1.93	18.40	29.22	18.64
Price / Book	0.48	3.57	10.77	4.77
Net Income	-$1.43B	$228.19M	$3.58B	$1.06B
7 Day Performance	-9.27%	-2.31%	-2.10%	-0.23%
1 Month Performance	-7.41%	-0.62%	3.29%	-0.11%
1 Year Performance	-62.92%	-2.73%	26.34%	16.46%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	3.8332 of 5 stars	$10.17 -0.5%	$19.33 +90.2%	-63.1%	$1.41B	$4.25B	N/A	8,100
SUPN Supernus Pharmaceuticals	3.0653 of 5 stars	$47.24 -1.7%	$62.17 +31.6%	+43.0%	$2.79B	$718.95M	N/A	580
NKTR Nektar Therapeutics	3.1659 of 5 stars	$73.15 +3.0%	$149.63 +104.5%	+173.2%	$2.40B	$55.23M	N/A	220	Positive News
PCRX Pacira BioSciences	2.1768 of 5 stars	$25.59 +0.8%	$29.40 +14.9%	+11.5%	$999.04M	$726.41M	213.27	720
OMER Omeros	3.9761 of 5 stars	$10.34 +11.4%	$38.00 +267.5%	+174.2%	$671.64M	N/A	14.77	210	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Summary

How does Perrigo compare to Nektar Therapeutics?

Summary

How does Perrigo compare to Pacira BioSciences?

Summary

How does Perrigo compare to Omeros?

Summary

How does Perrigo compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Do analysts rate SUPN or PRGO?

Which has more risk and volatility, SUPN or PRGO?

Which has better earnings and valuation, SUPN or PRGO?

Is SUPN or PRGO more profitable?

Does the media refer more to SUPN or PRGO?

Do insiders and institutionals hold more shares of SUPN or PRGO?

Summary

How does Perrigo compare to Nektar Therapeutics?

Which has more volatility & risk, PRGO or NKTR?

Do insiders and institutionals hold more shares of PRGO or NKTR?

Which has better valuation and earnings, PRGO or NKTR?

Do analysts recommend PRGO or NKTR?

Is PRGO or NKTR more profitable?

Does the media favor PRGO or NKTR?

Summary

How does Perrigo compare to Pacira BioSciences?

Do institutionals and insiders have more ownership in PRGO or PCRX?

Does the media prefer PRGO or PCRX?

Is PRGO or PCRX more profitable?

Which has more risk and volatility, PRGO or PCRX?

Which has preferable valuation and earnings, PRGO or PCRX?

Do analysts rate PRGO or PCRX?

Summary

How does Perrigo compare to Omeros?

Which has stronger valuation & earnings, PRGO or OMER?

Do insiders and institutionals believe in PRGO or OMER?

Do analysts prefer PRGO or OMER?

Does the media favor PRGO or OMER?

Which has more volatility and risk, PRGO or OMER?

Is PRGO or OMER more profitable?

Summary

How does Perrigo compare to Assembly Biosciences?

Do insiders and institutionals have more ownership in PRGO or ASMB?

Which has higher earnings & valuation, PRGO or ASMB?

Do analysts recommend PRGO or ASMB?

Does the media favor PRGO or ASMB?

Which has more volatility & risk, PRGO or ASMB?

Is PRGO or ASMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools